Rituxan (rituximab)

P2, N=43, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P1, N=25, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026

P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

P1, N=43, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025

P2, N=29, Recruiting, The First Affiliated Hospital of Soochow University

This case highlights the diagnostic limitation of endoscopic biopsy following rituximab therapy. Therefore, clinicians should be cautious in relying solely on endoscopic findings and remain open to surgical intervention to achieve a timely and accurate diagnosis.

Suggested by the DRESIS Database, NF-κB and Notch signaling cascades are key to the resistance of Doxorubicin (Dox) and cyclophosphamide (CTX) within the standard R-CHOP regimen of DLBCL hinting benefits of combining Spautin-1 with Dox or CTX. Altogether, these results demonstrate USP13 deubiquitinates Ran in DLBCL, and Spautin-1 well synergizes with Dox or CTX to initiate ferroptosis. Combinational treatment with Spautin-1 and Dox or CTX may represent an effective approach and therapeutic hope to combat with DLBCL.

The patient achieved complete remission with R-CHOP therapy, aligning with LBCL-IRF4-R's favorable prognosis. This case underscores the need for integrated morphology, immunophenotyping, and NGS to resolve complex diagnostic challenges. It presents a key diagnostic pitfall where secondary 11q aberrations in LBCL-IRF4-R can mimic HGBL-11q, revealing limitations of current genetic algorithms and advocating for expanded molecular diagnostic criteria.

This study presents flow cytometry-based assessment of Rituximab efficacy in Libyan B cell lymphoma patients, providing novel population-specific data.

He was treated with R-CHOEP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, and etoposide), which was later switched to R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) due to treatment-related neutropenia. The surgery was successful and there was no residual disease observed. This case highlights the diagnostic challenges of DLBCL presenting with isolated splenic infarction, emphasizing the role of PET/CT and biopsy in evaluation.

Proteome profiles of DLBCL cells were analyzed through groupwise comparison between cell lines with a resistant or sensitive response to rituximab, cyclophosphamide, doxorubicin, and vincristine. Enrichment of DNA damage repair proteins was observed within the differential proteins, highlighting the need to investigate DNA damage repair involvement in treatment responses. This study identifies 16 proteins with concordant treatment response specificity in DLBCL cell lines and lymphoma tissue patient samples, suggesting their potential as prognostic markers for DLBCL.

P3, N=300, Recruiting, Staidson (Beijing) Biopharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting